ROCKVILLE, Md., March 2 /PRNewswire-FirstCall/ -- InforMedix Holdings, Inc. (BULLETIN BOARD: IFMX) today shared the capability of its Med-e-Monitor(TM) System to enhance patient drug safety. Med-e-Monitor helps ensure the “Five Rights to Patient Drug Safety” -- The Right Patient, given the Right Drug, in the Right Dose, at the Right Time, through the Right Route of administration.
The National Council for Patient Information and Education states that outpatient medication non-compliance rates average 50% and result in over 125,000 preventable deaths and tens of billions of dollars in unnecessary costs each year. On average, a single medication error can cost the healthcare system $4,600. Congress and the FDA have been intensively focused on patient drug safety in recent weeks, and the FDA has announced the creation of a new, independent Drug Safety Oversight Board to better ensure safe drug administration to patients.
The Med-eMonitor System provides each patient with an individualized daily treatment regimen involving medication prompts and drug dispensing, behavioral prompts, medical education, and health status questionnaires. It provides warnings and alerts to the patient when the wrong drug is about to be taken, and provides warnings and alerts when a drug is missed to both the patient and the care coordinator. The System also captures side effect and adverse event information, provides instant alerts and recommendations for action to the patient, and triggers e-mail alerts to care managers and physicians to prompt urgent interventions that improve safety.
The Med-eMonitor System enables the capture and correlation of critical dose-response data, including the correlation of patient medication compliance data with patient reported outcomes, side effects, adverse events, and laboratory data, which assist in the scientific evaluation of a particular drug’s safety profile. Med-eMonitor also has medication compartments adjacent to the informational display on the device, whereby the display indicates and points to the correct compartment to access the medication at the time of administration, further improving safe medication administration.
Dr. Bruce Kehr, CEO of InforMedix stated, “Studies conducted in Congestive Heart Failure and Schizophrenia populations have shown that the Med-e-Monitor System provides medication compliance and care plan adherence rates in excess of 90%. Our alliance with McKesson BioServices, a leader in patient medication systems, further supports the success of the Med-eMonitor System in this capacity.”
InforMedix has developed the Med-eMonitor System to provide real-time medical management and patient communications for clinical drug trials and disease management markets. InforMedix has integrated a portable patient- interactive monitoring device, hardware, software and networked communications system to enable pharmaceutical and biotechnology companies, medical researchers, and disease management programs to efficiently monitor and manage patients’ medication compliance, protocol adherence, clinical response, and drug safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in clinical drug trials and disease management programs. The Med-eMonitor System leverages InforMedix’s strong intellectual property consisting of 15 issued patents and 14 patents pending. InforMedix’s patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (BULLETIN BOARD: IFMX) , visit our website at http://www.informedix.com/.
This report contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. References made to the discussion of the risk factors are detailed in the Company’s filings with the Securities and Exchange Commission, including the report on Form 10-QSB for the quarter ended September 30, 2004, our Annual Report on Form 10-KSB for the year ended December 31, 2003, our prospectus dated May 28, 2004 and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Corporate Investor Relations Bruce A. Kehr, M.D. Rachel Levine Chief Executive Officer Managing Director InforMedix, Inc. The Anne McBride Company T: 301-984-1566 Tel: 212-983-1702 x207 E: rlevine@annemcbride.com
InforMedix Holdings, Inc.
CONTACT: Bruce A. Kehr, M.D., Chief Executive Officer of InforMedix,Inc., +1-301-984-1566; or Investor Relations - Rachel Levine, ManagingDirector of The Anne McBride Company, +1-212-983-1702, x207,rlevine@annemcbride.com, for InforMedix, Inc.
Web site: http://www.informedix.com/